| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 3.9 | 1.6 | 0.3 |
| Other income | 0.1 | 0.1 | 1.0 |
| Total income | 4.0 | 1.6 | 1.4 |
| Profit before exceptional items & tax | 0.1 | 0.0 | 0.8 |
| Profit before tax | 0.1 | 0.0 | 0.8 |
| Net profit | 0.1 | 0.0 | 0.8 |
| Operating margin | 2.5% | 0.0% | 57.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -87.50% |
|---|---|
| Revenue, year on year | +1200.00% |
BSE results filing, NSE: VENMAX. Figures extracted from the filing.
Venmax Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹14.89
- Market cap
- ₹13.08 Cr
- Revenue (annual)
- ₹8.02 Cr
- Net profit (annual)
- ₹0.25 Cr
- P/E (TTM)
- 46.7×Sector 47.3×
- Promoter holding
- 10.46%-3.34% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Venmax Drugs & Pharmaceuticals Ltd
All →Venmax Drugs & Pharmaceuticals Annual General Meeting
Venmax Drugs and Pharmaceuticals held its 37th Annual General Meeting on September 26, 2026. Shareholders considered the financial statements and various directorship appointments.
Venmax Drugs & Pharmaceuticals Acquisition
Venmax Drugs and Pharmaceuticals Limited announced an NCLT-convened meeting of equity shareholders on October 24, 2026, to consider the proposed merger with Hatri Pharma Private Limited.
Venmax Drugs & Pharmaceuticals Acquisition
NCLT Hyderabad directed Venmax to convene a shareholder meeting on 24 Oct 2026 for the amalgamation of Hatri Pharma into Venmax. The order also dispensed with meetings of Hatri Pharma's shareholders and creditors.
Venmax Drugs & Pharmaceuticals Annual Report
Venmax Drugs and Pharmaceuticals Limited has submitted its Annual Report for the Financial Year 2025-26, including the Notice for its 37th Annual General Meeting.
Venmax Drugs & Pharmaceuticals Board Meeting Outcome
Venmax Drugs held a board meeting to approve the Directors' Report, AGM date, and appoint/regularize key directors. The meeting outcomes were disclosed under Regulation 30.
Venmax Drugs & Pharmaceuticals Board Meeting Date
Venmax Drugs & Pharmaceuticals scheduled a board meeting for August 31, 2026. The board will approve the 37th Annual Report and fix details for the Annual General Meeting.